Filtros de búsqueda

Lista de obras de

24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy ⬇️

artículo científico publicado el 28 de octubre de 2011

Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).

artículo científico publicado en 2017

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) randomized trial

artículo científico publicado en 2020

Combined Olmesartan, Amlodipine, and Hydrochlorothiazide Therapy in Randomized Patients with Hypertension: A Subgroup Analysis of the TRINITY Study by Age ⬇️

artículo científico publicado el 1 de julio de 2013

Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial

artículo científico publicado en 2020

Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis

scientific article published on 01 November 2019

Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

artículo científico publicado en 2016

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

artículo científico publicado en 2020

Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension

artículo científico publicado en 2009

Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study ⬇️

artículo científico publicado el 26 de octubre de 2011

IMPACT OF BODY MASS INDEX AND OBESITY ON CLINICAL OUTCOMES IN THE EDOXABAN VERSUS WARFARIN IN SUBJECTS UNDERGOING CARDIOVERSION OF ATRIAL FIBRILLATION (ENSURE-AF) RANDOMIZED TRIAL

article

Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF)

artículo científico publicado en 2018

Long‐Term Efficacy and Safety of Triple‐Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension ⬇️

artículo científico publicado el 24 de enero de 2012

Model-Supported Development of CS-8635: A Fixed-Dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

artículo científico publicado en 2013

Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis

artículo científico publicado en 2013

Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study ⬇️

artículo científico publicado el 30 de octubre de 2012

Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).

artículo científico publicado en 2017

Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial

scientific article published on 22 November 2018

Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.

artículo científico publicado en 2009

The TRINITY Study: distribution of systolic blood pressure reductions ⬇️

artículo científico publicado el 12 de julio de 2013

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

artículo científico publicado en 2008

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study ⬇️

artículo científico publicado el 1 de julio de 2010

Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study

artículo científico publicado en 2012

Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study

artículo científico publicado en 2014

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda